News

Media

Conferences

Publications

Clinical

Events

Resources

Video

January 27, 2022

Trends in the Advancement of Health Care IT in 2022, Beyond

Shreejit Nair, senior vice president and life sciences market business lead at CitiusTech, discusses some trends and predictions for health care IT this year and on into the future.

Pharmacy Times interviewed Shreejit Nair, senior vice president and life sciences market business lead at CitiusTech, on how data interoperability can be enhanced within pharmacy and health systems to improve health care outcomes.

During the interview, Nair discussed some trends and predictions for advancements in the field of health care IT in 2022 and beyond.

Related Videos

Related Content

Sleepless, man suffering from insomnia, sleep apnea or stress. Tired and exhausted guy. Headache or migraine. Awake in the night.

December 20th 2024

FDA Approves Tirzepatide as First Treatment for Moderate-to-Severe Obstructive Sleep Apnea in Adults With Obesity

Luke Halpern, Assistant Editor

Public Health Matters: Pharmacists as Frontline Health Providers: Collaborating for Better Patient Outcomes

November 21st 2024

Public Health Matters: Pharmacists as Frontline Health Providers: Collaborating for Better Patient Outcomes

Christina M. Madison, PharmD, FCCP, AAHIVP

Varicella zoster or chickenpox virus, ai illustration. A herpes virus which cause chickenpox and shingles - Image credit: Cristina | stock.adobe.com

December 20th 2024

Study: Fatal Disseminated Herpes Zoster in Immunocompetent Individuals

Kennedy Ferruggia, Assistant Editor

September 19th 2024

Public Health Matters: The Difference Between Misinformation and Disinformation, and How Information Can Inform Evidence-Based Decisions

Close up image of skin texture suffering severe urticaria or hives or kaligata on back.

December 20th 2024

Patients With Chronic Idiopathic Urticaria at Higher Risk of Developing Food Allergies

Luke Halpern, Assistant Editor

Mounjaro tirzepatide GLP-1 receptor agonist vial | Image Credit: © Cynthia - stock.adobe.com

December 20th 2024

FDA Affirms Decision on Tirzepatide Shortage Resolved, Sets Transition Period for Compounding

Alexandra Gerlach, Associate Editor

Related Content

Sleepless, man suffering from insomnia, sleep apnea or stress. Tired and exhausted guy. Headache or migraine. Awake in the night.

December 20th 2024

FDA Approves Tirzepatide as First Treatment for Moderate-to-Severe Obstructive Sleep Apnea in Adults With Obesity

Luke Halpern, Assistant Editor

Public Health Matters: Pharmacists as Frontline Health Providers: Collaborating for Better Patient Outcomes

November 21st 2024

Public Health Matters: Pharmacists as Frontline Health Providers: Collaborating for Better Patient Outcomes

Christina M. Madison, PharmD, FCCP, AAHIVP

Varicella zoster or chickenpox virus, ai illustration. A herpes virus which cause chickenpox and shingles - Image credit: Cristina | stock.adobe.com

December 20th 2024

Study: Fatal Disseminated Herpes Zoster in Immunocompetent Individuals

Kennedy Ferruggia, Assistant Editor

September 19th 2024

Public Health Matters: The Difference Between Misinformation and Disinformation, and How Information Can Inform Evidence-Based Decisions

Close up image of skin texture suffering severe urticaria or hives or kaligata on back.

December 20th 2024

Patients With Chronic Idiopathic Urticaria at Higher Risk of Developing Food Allergies

Luke Halpern, Assistant Editor

Mounjaro tirzepatide GLP-1 receptor agonist vial | Image Credit: © Cynthia - stock.adobe.com

December 20th 2024

FDA Affirms Decision on Tirzepatide Shortage Resolved, Sets Transition Period for Compounding

Alexandra Gerlach, Associate Editor

Consent Preferences

Clinical Forums

Editorial Staff

Terms & Conditions

Do Not Sell My Information

Contact Info

2 Commerce Drive
Cranbury, NJ 08512

© 2024 MJH Life Sciences

All rights reserved.